Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge

Capricor Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant uptick in its stock performance today, gaining 9.78%. The stock reached an intraday high of USD 31.41, showcasing notable activity amid broader market trends. Over the past week, Capricor has outperformed the S&P 500 with a 14.04% increase, while its one-month performance stands at 21.6%. Impressively, the stock has surged by 139.11% over the past year, significantly outpacing the S&P 500's 17.78% gain. Furthermore, Capricor's three-year performance reflects a remarkable 557.3% increase, compared to the S&P 500's 73.44%. Despite these gains, the company has faced challenges, reporting negative results for the last four consecutive quarters. Key financial metrics indicate an operating cash flow of USD -61.04 million and a pre-tax profit of USD -24.57 million, both reflecting declines. The stock's trading position appears risky when compared to its historical valuations, with a return of 105.37% over the past year coinciding with a significant drop in profits.